8-Azabicyclo[3.2.1]octane, 3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-, (1R,2R,3S,5S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:)

8-Azabicyclo[3.2.1]octane, 3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-, (1R,2R,3S,5S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:) Suppliers list
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354 +1-00000000000
Email: marketing@targetmol.com
Products Intro: Product Name:NS-2359 citrate;GSK372475;NS2359;NS 2359;GSK-372475;GSK 372475;NS-2359
CAS:195875-69-5
Package:100 mg;500 mg Remarks:REAGENT;FOR LABORATORY USE ONLY
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Products Intro: Product Name:NS-2359 citrate
CAS:195875-69-5
Purity:0 Package:25mg/RMB 10600
8-Azabicyclo[3.2.1]octane, 3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-, (1R,2R,3S,5S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:) Basic information
Product Name:8-Azabicyclo[3.2.1]octane, 3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-, (1R,2R,3S,5S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:)
Synonyms:8-Azabicyclo[3.2.1]octane, 3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-, (1R,2R,3S,5S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:);GSK 372475;GSK372475;GSK-372475;NS-2359 citrate;NS2359 citrate,NS 2359 citrate
CAS:195875-69-5
MF:C22H29Cl2NO8
MW:506.37
EINECS:
Product Categories:
Mol File:195875-69-5.mol
8-Azabicyclo[3.2.1]octane, 3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-, (1R,2R,3S,5S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:) Structure
8-Azabicyclo[3.2.1]octane, 3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-, (1R,2R,3S,5S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:) Chemical Properties
Safety Information
MSDS Information
8-Azabicyclo[3.2.1]octane, 3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-, (1R,2R,3S,5S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:) Usage And Synthesis
DescriptionNS-2359 is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant, but was discontinued in 2009 when phase II clinical trials turned up disappointing results and did not support further effort by the company. NS-2359 was also in clinical trials for the treatment of ADHD, phase II having been completed in 2007. A trial exploring the effect of NS-2359 on cocaine-experienced individuals is currently ongoing.
8-Azabicyclo[3.2.1]octane, 3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-, (1R,2R,3S,5S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:) Preparation Products And Raw materials
Tag:8-Azabicyclo[3.2.1]octane, 3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-, (1R,2R,3S,5S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:)(195875-69-5) Related Product Information